In November 2019, a class-action lawsuit
was filed against AMAG, Inc. for allegedly falsely marketing Makena as a medication that “lower[s] the risk of having another preterm baby in women who are pregnant with one baby, and who’ve unexpectedly delivered one baby too early (before 37 weeks) in the past” when, according to plaintiffs, scientific evidence does not support such claims. (Faughnan et al v. AMAG, Inc.
, Case No. 19-cv-1394, N. D. NY.)